Les immune-checkpoints dans les hémopathies

Thanarajasingam, 2016, Immune checkpoint blockade in lymphoid malignancies, FEBS J, 283, 2233, 10.1111/febs.13668 Schreiber, 2005, Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting, Cancer Immun, 5, 1 Georgiou, 2016, Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas, Blood, 127, 3026, 10.1182/blood-2015-12-686550 Twa, 2015, Recurrent genomic rearrangements in primary testicular lymphoma: genomic rearrangements in primary testicular lymphoma, J Pathol, 236, 136, 10.1002/path.4522 Twa, 2014, Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma, Blood, 123, 2062, 10.1182/blood-2013-10-535443 Van Roosbroeck, 2016, Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies: JAK2 and PDL1/2 aberrations in lymphoma, Genes Chromosomes Cancer, 55, 428, 10.1002/gcc.22345 Green, 2012, Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy, Clin Cancer Res, 18, 1611, 10.1158/1078-0432.CCR-11-1942 Gupta, 2012, Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation, Blood, 119, 2844, 10.1182/blood-2011-10-388538 Kasprzycka, 2006, Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3, Proc Natl Acad Sci U S A, 103, 9964, 10.1073/pnas.0603507103 Chapuy, 2016, Targetable genetic features of primary testicular and primary central nervous system lymphomas, Blood, 127, 869, 10.1182/blood-2015-10-673236 Weniger, 2006, Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation, Oncogene, 25, 2679, 10.1038/sj.onc.1209151 Navarro, 2009, Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma, Blood, 114, 2945, 10.1182/blood-2009-02-204842 Marzec, 2008, Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1), Proc Natl Acad Sci U S A, 105, 20852, 10.1073/pnas.0810958105 Choi, 2013, MYD88 expression and L265P mutation in diffuse large B-cell lymphoma, Hum Pathol, 44, 1375, 10.1016/j.humpath.2012.10.026 Alizadeh, 2000, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, 403, 503, 10.1038/35000501 Ahearne, 2014, Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma, Virchows Arch Int J Pathol, 465, 351, 10.1007/s00428-014-1615-5 Kiyasu, 2015, Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, 126, 2193, 10.1182/blood-2015-02-629600 Muenst, 2010, Diagnostic and prognostic utility of PD-1 in B cell lymphomas, Dis Markers, 29, 47, 10.1155/2010/404069 Laurent, 2015, Several immune escape patterns in non-Hodgkin's lymphomas, Oncoimmunology, 4, e1026530, 10.1080/2162402X.2015.1026530 Tonino, 2012, Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia, Leuk Lymphoma, 53, 1785, 10.3109/10428194.2012.673224 Xerri, 2008, Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia, Hum Pathol, 39, 1050, 10.1016/j.humpath.2007.11.012 Kwon, 2016, Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas, Histopathology, 68, 1079, 10.1111/his.12882 Andorsky, 2011, Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells, Clin Cancer Res, 17, 4232, 10.1158/1078-0432.CCR-10-2660 Chen, 2013, PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res, 19, 3462, 10.1158/1078-0432.CCR-13-0855 Laurent, 2016, Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients, Haematologica, 101, 976, 10.3324/haematol.2016.141978 Magnoli, 2015, Primary testicular diffuse large B-cell lymphoma: morphological and immunophenotypical study with characterization of the T-cell component of the tumor microenvironment, Leuk Lymphoma, 1 Riemersma, 2005, High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis, J Pathol, 206, 328, 10.1002/path.1783 Rajnai, 2014, The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone, Virchows Arch Int J Pathol, 464, 229, 10.1007/s00428-013-1519-9 Berghoff, 2014, PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL), Clin Neuropathol, 33, 42, 10.5414/NP300698 Chapuy, 2016, Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease, Blood, 127, 2203, 10.1182/blood-2015-09-672352 Steidl, 2011, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, 471, 377, 10.1038/nature09754 Menter, 2016, Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas, Hum Pathol, 54, 17, 10.1016/j.humpath.2016.03.005 Dorfman, 2006, Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma, Am J Surg Pathol, 30, 802, 10.1097/01.pas.0000209855.28282.ce Richendollar, 2011, Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma, Hum Pathol, 42, 552, 10.1016/j.humpath.2010.08.015 Ramsay, 2012, Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer, Blood, 120, 1412, 10.1182/blood-2012-02-411678 Carreras, 2009, High numbers of tumor-infiltrating programmed cell death 1 – positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma, J Clin Oncol, 27, 1470, 10.1200/JCO.2008.18.0513 Wahlin, 2010, A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1 – positive, regulatory, cytotoxic, and helper T cells and macrophages, Clin Cancer Res, 16, 637, 10.1158/1078-0432.CCR-09-2487 Smeltzer, 2014, Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma, Clin Cancer Res, 20, 2862, 10.1158/1078-0432.CCR-13-2367 Laurent, 2011, Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study, Blood, 118, 5371, 10.1182/blood-2011-04-345777 Yang, 2015, PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival, Blood Cancer J, 5, e281, 10.1038/bcj.2015.1 Brusa, 2013, The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia, Haematologica, 98, 953, 10.3324/haematol.2012.077537 Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 Wilcox, 2009, B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders, Blood, 114, 2149, 10.1182/blood-2009-04-216671 Brown, 2003, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production, J Immunol, 170, 1257, 10.4049/jimmunol.170.3.1257 Cetinözman, 2012, Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides, Arch Dermatol, 148, 1379, 10.1001/archdermatol.2012.2089 Cetinözman, 2012, Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma, Am J Surg Pathol, 36, 109, 10.1097/PAS.0b013e318230df87 Kozako, 2009, PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients, Leukemia, 23, 375, 10.1038/leu.2008.272 Engert, 2012, Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial, Lancet, 379, 1791, 10.1016/S0140-6736(11)61940-5 Gordon, 2013, Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496), J Clin Oncol, 31, 684, 10.1200/JCO.2012.43.4803 Evens, 2008, Treatment of Hodgkin lymphoma: the past, present, and future, Nat Clin Pract Oncol, 5, 543, 10.1038/ncponc1186 Montanari, 2015, Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy, Clin Adv Hematol Oncol, 13, 518 Johnson, 2015, Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis, Int J Cancer, 137, 1066, 10.1002/ijc.29467 Pantanowitz, 2015, Microenvironment and HIV-related lymphomagenesis, Semin Cancer Biol, 34, 52, 10.1016/j.semcancer.2015.06.002 Reichel, 2015, Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells, Blood, 125, 1061, 10.1182/blood-2014-11-610436 Plattel, 2012, Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma, Haematologica, 97, 410, 10.3324/haematol.2011.053199 Yamamoto, 2008, PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma, Blood, 111, 3220, 10.1182/blood-2007-05-085159 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Koh, 2016, Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma, Tumour Biol, 37, 7507, 10.1007/s13277-015-4622-5 Green, 2010, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, Blood, 116, 3268, 10.1182/blood-2010-05-282780 Steidl, 2010, Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome, Blood, 116, 418, 10.1182/blood-2009-12-257345 Muenst, 2009, Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival, Hum Pathol, 40, 1715, 10.1016/j.humpath.2009.03.025 Muenst, 2015, The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy, Expert Opin Ther Targets, 19, 201, 10.1517/14728222.2014.980235 Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001